This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The current pandemic of COVID-19 infection worries the world, due to high morbidity and mortality. Various strategies for infection control, including nutritional interventions, have been considered, given the extremely rapid spread of the disease, the lack of specific effective and safe antiviral treatment and the difficulty of having a vaccine in the near future. Vitamin C, long known for its antioxidant and anti-infective effects, has been analyzed from the perspective of biochemical mechanisms with potential benefits in patients with severe COVID-19 infection. Favorable clinical results have been reported after intravenous administration of high doses of Vitamin C, but confirmation of these data requires extensive studies.

Conclusion DRV/r administered in combination with other ARV medications in subtype F HIV-1 infected subjects in naturalistic settings proved to be an effective and safe treatment in Romania.Trial registration NCT01253967

The oral mucosa is a mirror of the state of health for the whole organism, representing a natural barrier to infection, an entry gate for a large number of pathogens, a site for microbial multiplication and for initiating disease- specific pathological processes, expressed by lesions, signs and symptoms characteristic for diagnosis. The new global threat to public health, COVID-19 infection can be customized within the oral pathology. The new SARS-CoV-2 coronavirus is characterized by high contagiousness, airborne transmission, directly through inhaled drops or, indirectly, through the use of contaminated objects. The survival of the virus on surfaces, depending on their structure, varies from 4 hours to 9 days. The initiation of infection is possible through the binding of viruses in site of host cells, due to receptor affinity and an angiotensin converting enzyme (ACE2), distributed in the epithelium, alveoli, ascular endothelium, lung pneumocytes and macrophage. The severity of the infection varies from asymptomatic forms to severe complications, with high motility. In the absence of a treatment or vaccine with proven efficacy, to be approved for use in practice, prevention is limited to respecting hygiene and social spacing, proper use of protective equipment and limiting services and procedures at risk of dispersing aerosols and saliva.

No abstract